1408238-37-8

Basic information

• Product Name: Dabigatran Impurity p
• Synonyms: 3-(2-(((4-(((hexyloxy)carbonyl)carbamoyl)phenyl)amino)methyl)-1-methyl-N-(pyridin-2-yl)-1H-benzo[d]imidazole-5-carboxamido)propanoic acid;BIBR1155
• CAS NO: 1408238-37-8
• Molecular Formula: C₃₂H₃₆N₆O₆
• Molecular Weight: 600.66484
• Mol File: 1408238-37-8.mol
• Article Data: 2

Chemical Properties

• Appearance: /
• Density: 1.29±0.1 g/cm3(Predicted)
• Storage Temp.: Refrigerator
• Solubility: DMSO (Slightly), Methanol (Slightly, Heated)
• PKA: 4.17±0.10(Predicted)
• CAS DataBase Reference: Dabigatran Impurity p(CAS DataBase Reference)
• NIST Chemistry Reference: Dabigatran Impurity p(1408238-37-8)
• EPA Substance Registry System: Dabigatran Impurity p(1408238-37-8)

Safety Data

• Hazardous Substances Data: 1408238-37-8(Hazardous Substances Data)

Usage

Uses

N-[[2-[[[4-[[[(Hexyloxy)carbonyl]amino]carbonyl]phenyl]amino]methyl]-1-methyl-1H-benzimidazol-5-yl]carbonyl]-N-2-pyridinyl-β-alanine is an impurity of Dabigatran Etexilate Mesylate (D100150) which is a nonpeptide, direct thrombin inhibitor.

Upstream product

• 1415506-19-2 3-[[[2-[[[4-[amino[[[(hexyloxy)carbonyl]amino]methyl]]phenyl]amino]methyl]-1-methyl-1H-benzimidazol-5-yl]carbonyl](pyridin-2-yl)amino]propionic acid 
• 211915-06-9 dabigatran etexilate 
• 429658-95-7 3-({2-[(4-carbamimidoylphenylamino)methyl]-1-methyl-1H-benzoimidazole-5-carbonyl}pyridin-2-yl-amino)propionic acid ethyl ester 
• 873-74-5 4-Aminobenzonitrile 
• 42288-26-6 (4-cyanophenyl)glycine 

Relevant articles and documents

DABIGATRAN ETEXILATE AND RELATED SUBSTANCES, PROCESSES AND COMPOSITIONS, AND USE OF THE SUBSTANCES AS REFERENCE STANDARDS AND MARKERS

The present invention relates to dabigatran etexilate and related substances and use of the substances as reference standards and markers. There are also provided processes of detecting the substances in samples of dabigatran etexilate, or pharmaceutically acceptable salts or solvates thereof, and also for analyzing the purity of samples of dabigatran etexilate, or pharmaceutically acceptable salts or solvates thereof.There are still further provided processes of preparing dabigatran etexilate and related substances, and pharmaceutical compositions containing the same.